03/31/23 8:00 AMNasdaq : LIPO earningslow floatLipella Provides Business Update and Reports 2022 Financial ResultsCompany Successfully Completes Phase 2a Clinical TrialFourth Quarter or Full Year Highlights • Appointed Douglas Johnston as CFO in November 2022 • Successfully completed Initial Public Offering, attained NASDAQ CM listing • Year-end cash balance in excess of $5 millionSubsequent Events •RHEA-AIpositive
03/16/23 8:30 AMNasdaq : LIPO clinical triallow floatLipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological AssociationLipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company") today announced the successful completion of a Phase 2A clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for hemorrhagic cystitis.TheRHEA-AIneutral
03/01/23 8:00 AMNasdaq : LIPO managementlow floatLipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory BoardLipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announcedRHEA-AIvery positive
01/11/23 7:30 AMNasdaq : LIPO clinical triallow floatLipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company focused on developing new drugs byRHEA-AIneutral
01/09/23 8:00 AMNasdaq : LIPO conferenceslow floatLipella Pharmaceuticals to Present at January 2023 Biotech Showcase in San FranciscoLipella Pharmaceuticals Inc. (Nasdaq: LIPO) ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company focused on developing new drugs by reformulating theRHEA-AIvery positive
